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1. Introduction 
Metastasis is the leading cause of cancer death and in patients with proven distant 
metastases from solid tumors, it has been a notion that the condition is incurable and the 
treatment is usually conducted with palliative intent, with rare exceptions. Treatment 
predominantly involves the use of systemic chemotherapy, targeted radiotherapy or local 
measures typically reserved for symptom relief (Argiris, 2004; Escudier, 2007; Hurwits, 
2004). Chemotherapy is delivered without expectation of long term survival, except for 
highly chemosensitive malignancies, such as leukemia, lymphoma, and germ cell tumors. 
According to the conventional treatment strategy for solid tumors, the presence of 
metastatic disease is a contraindication for local therapy because it is believed that these 
tumor cells have already spread systemically. However, from the viewpoint of reducing 
tumor burden, local therapy may be an adequate strategy when the target lesions account 
for the major portion of the total tumor volume. The local therapies are metastasectomy, 
heating or cooling, and radiotherapy. 
In a subset of patients with a limited number of metastases or oligometastases, local ablative 
therapy, such as surgical resection, can potentially yields favorable outcomes. For instance, in 
surgical literature, it has been demonstrated that surgical resection of limited lung and liver 
metastases has results in prolonged survival and possibly cure in a significant proportion of 
patients with oligometastases (Fong, 1999; Friedel, 1994). International registry of lung 
metastases reported that lung metastasectomy is a safe and curative procedure in selected 
patients with disease free interval (DFI) ≥ 3 years, single lesion and germ cell tumor (Pastorino, 
1997). And the lung and liver metastasectomy is a surgical approach used in colon and breast 
cancers, with upto 22% of colon cancer patients surviving 10 years and 35-46% of breast cancer 
patients surviving upto 5 years (Fong et al, 1999; Friedel et al, 1994; Pocard et al, 2001). 
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However, resection may not be feasible in patients of extremely advanced age or with poor 
cardiopulmonary function or multiple comorbidities because of the risk of significant 
morbidity and mortality in these settings. In such patients, external radiotherapy is often the 
treatment of choice. However, this treatment also has its drawbacks, including the potential to 
damage adjacent or nearby structures and its association with a local failure rate that is higher 
than that was seen in resection. To minimize collateral injury to normal tissues, adequate 
fractionation (e.g. 1.8-2.0 Gy/fraction) over 6 to 7 weeks is commonly used. The use of 
radioablative treatment such as using stereotactic radiosurgery (SRS) or stereotactic body 
radiotherapy (SBRT) to overcome problems with normal tissue injury in patients with 
medically inoperable metastatic tumor has now been actively studied at many institutions. 
2. Oliogmetastases 
2.1. Definition 
In 1889, Paget’s “seed and soil” hypothesis stated that the development of a metastasis 
depends on cross talk between selected cancer cells (the seed) and a specific organ 
microenvironment (the soil) (Paget, 1889). This means that successfully establishing a distant 
metastasis depends on certain properties of the host organ as well as those of tumor cells. 
Dissemination of tumor cells in general circulation does not necessarily mean that wide 
spread metastatic disease will always develop. This hypothesis is still widely accepted. 
Observing the natural history of breast cancer, Hellmann and Weichselbaum hypothesized 
the existence of an intermediate state between widespread metastatic disease and locally 
confined disease and coined the term “oligometastases” (Hellman & Weichselbaum, 1995). 
Thus, local control of oligometastatic disease may allow better systemic control. In addition, 
thanks to the evolution of radiologic imaging technique, detection of metastasis at a size 
previously impossible to be detected may result in under treatment and an effective 
chemotherapy may downstage these metastatic diseases to oligometastases. 
2.2. Clinical significance 
Clinically, there are two types of oligometastases. The De novo type is the tumor early in the 
evolution of metastatic progression producing metastasis that are limited in number and 
location, and the induced type is generated when effective systemic chemotherapy 
eradicates the majority of metastatic deposits in a patients with wide spread metastatic 
disease (MacDermed, 2008). 
 In a retrospective study, Mehta et al tracked the number of individual metastatic sites and 
the number of organs involved using serial computerized tomography of the body in 38 
patients with stage IIIb or IV non small cell lung cancer treated with chemotherapy. Seventy 
four percent of patients (n=28) had a metastatic disease limited to 1-2 organs and 50% (n=29) 
had a disease limited to the primary tumor and three or less metastatic lesions at 
presentation. Fifty percent (n=19) had stable (n=12) or progressive (n=7) disease in initially 
involved site without development of new metastatic lesion. Among the 17 patients with 
four or fewer metastatic sites with no pleural effusions, 65% (n=11) had stable or progressive 
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disease in initially involved sites without development of new metastatic lesions (Mehta, 
2004). The results of this study suggest that a subset of patients with oligometastases from 
lung cancer may benefit from a combination of systemic chemotherapy and local aggressive 
therapy. In another study, records of 387 patients with advanced non small cell lung cancer 
were reviewed and 64 patients with measurable advanced stage non small cell lung cancer 
who received first line systemic chemotherapy and follow up were identified. Thirty four 
patients were deemed theoretically SBRT eligible. Disease in the lung and liver was limited 
to ≤ 3 sites each. Among the 34 SBRT eligible patients, the pattern of failure were local only 
in 68%, distant only in 14%, and mixed in 18%. The time to first progression was 3.0 months 
in those with local only failure (Rusthoven, 2009). The results of this study suggest that 
SBRT may improve the time to first progression in a significant proportion of patients with 
metastatic non small cell lung cancer. After all, because any patient with oligometastatses 
may exist in a spectrum between orderly metastatic progressions and wide spread occult 
disease, the role of the local modality to ablate oligometastases need to be determined. 
3. Stereotactic Body Radiation Therapy (SBRT) 
3.1. Definition and characteristics 
The scientific study and clinical practice of oncology have progressed remarkably in recent 
years. Insights into molecular interactions occurring within a cancer cell have been 
translated into novel medical treatments, and a variety of technological advances have 
allowed new surgical and radiotherapeutic techniques. Within the discipline of radiation 
oncology in particular, the fusion of state-of the-art tumor imaging with precision radiation 
treatment delivery systems has created an opportunity to shift from the classic radiation 
therapy paradigm of administering thirty or more individual allow-dose treatments toward 
briefer, more intense, and more potent regimens in which a much higher dose per treatment 
is used for greater clinical effect. Stereotactic body radiation therapy (SBRT) refers to an 
emerging radiotherapy procedure that is highly effective in controlling early stage primary 
and oligometastatic cancers at locations throughout the abdominopelvic and thoracic 
cavities, and at spinal and paraspinal sites. The major feature that separates SBRT from 
conventional radiation treatment is the delivery of large doses in a few fractions, which 
results in a high biological effective dose (BED). In order to minimize the normal tissue 
toxicity, conformation of high doses to the target and rapid fall-off doses away from the 
target is critical. The practice of SBRT therefore requires a high level of confidence in the 
accuracy of the entire treatment delivery process. 
In SBRT, radiation is targeted almost exclusively to the tumor, while tissues not grossly 
involved with the tumor are spared. However, unique radiobiology of SBRT that ensures 
maximal tumor control but minimal normal tissue complication is what really sets SBRT 
apart from other radiotherapy techniques. Additional defining characteristics of SBRT 
include the abilities to securely immobilize the patient for the typically long treatment 
sessions; to accurately duplicate patient position between simulation and treatment; to 
minimize normal tissue exposure through the use of multiple- or large angle, arcing, small-
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aperture fields; to rigoursly account for organ motion; to stereoctactically register tumor 
target and normal tissue structures; and to deliver ablative dose fractions with 
subcentimeter accuracy to the patient (Timmerman, 2007). 
Immobilization and repositioning devices include the Elekta Stereotactic Body Frame™ 
(Elekta, Norcross, Ga., USA), the Leibinger stereotactic body fixation system (Stryker, 
Kalamazoo, Mich., USA), and the Medical Intelligence Bodyfix™ system (Medical 
Intelligence, Schwabmuenchen, Germany).  
Several systems provide one or another solution to the problem of respiratory motion. A 
breath-hold device is the Active Breathing Coordinator™ (Elekta), which allows coordination 
of beam-on time during a fixed level of inspiration; a respiratory gating system is the RPMTM 
(Varian, Palo Alto, USA) which tracks inspiration and expiration and turns the accelerator off 
when indicators predict that the tumor position is outside of an acceptable range of distance 
from baseline; a another gating system is the ANZAI (Anzai, Japan). 
 
Figure 1. Various system of Stereotactic Body Radiation Therapy (SBRT) 
(a) Siemens (CT on Rail) (b) Tomotherapy (c) Elekta 
(d) Cyberknife (e) VERO (f) Varian 
(g) Novalis 
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Also now available for purchase are specialized SBRT-ready linear accelerators that combine 
capacity for image-guided radiotherapy with compatibility with modern immobilization 
and respiratory motion solution technology. The Novalis™ (BrainLAB, Inc.), Elekta 
Synergy™, Varian Trilogy™, Siemens Atiste™ System, Tomotherapy HiArt™ System 
(TomoTherapy, Madison, Wisc., USA), and Cyberknife™ (Accuray, Sunnyvale, Calif., USA) 
are linear accelerators for SBRT (Fig. 1).  
3.2. Radiobiologic aspect of Hypofractionated SBRT 
The most prevalent method of radiotherapy in the past 100 years of radiation oncology has 
been a strategy known as protracted fractionation in which daily small doses of radiation 
(e.g. 1.8~4 Gy) are delivered repeatedly over many days. The basis of this method of 
radiotherapy was that normal tissue repairs sublethal injury between fractions better than 
does tumor tissue. With the advent of SRS to treat intracranial tumors, an alternatively 
strategy of giving an ablative dose (e.g. 12~30 Gy) was born. A SBRT is an extension of this 
technique to deliver ablative radiotherapy (8~30 Gy) to extracranial sites. When alternate 
fractionation schemes are considered, we need some model for calculating isoeffect doses 
and a linear quadratic (LQ) formalism is most commonly used for quantitative prediction of 
dose/fractionation dependencies. The LQ model approximates clonogenic survival data with 
a truncated power series (second order polynomial) expansion of natural log of S (surviving 
proportion) as follows (see Equation 1). 
 2lnS * d * d      (1) 
The d is daily dose and α & β are expansion parameters: α is the slope of the survival curve 
at the limit d→0, and β is the parameter determining the relative contribution from the 
quadratic component (Fig. 2A). This model was initially derived to fit experimental 
observation of the effects of dose and fractionation on cell survival, chromosomal damage, 
and acute radiation effects. Later, some ascribed underlying biological mechanism to the 
mathematical terms, primarily the formation of single- and double-strand break in DNA. 
The LQ model has been useful for predicting and understanding the effects of conventional 
fractionated radiotherapy. The biological effective dose (BED) is a characteristic dose value 
that facilitated comparisons between the effects of different dose fractionation schemes. The 
BED is defined as the total dose delivered in an infinite number of infinitesimally small dose 
fractions that has the same biologic effect as the dose fractionation scheme in question and 
described as BED=D*[1+d/(α/β)]. 
This BED based on LQ model is known reasonably predictive of dose response relation, 
both in vivo and vitro, in the dose per fractions range of 2 to 15 Gy (Brenner, 2008), however, 
the LQ model predicts a continuously bending curve in the high dose range and 
experimentally measured data have decidedly shown a linear relationship between the dose 
and log of the proportion of surviving clonogen. In addition, in the early phase of its 
development, one of the developers of the LQ model stated that “LQ is not intended for 
doses higher than 8-10 Gy. In any case, LQ is simply a loose dose approximation to equation 
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Figure 2. Shape of survival curve for mammalian cells exposed to radiation. The fraction of cells 
surviving is plotted on a logarithmic scale against on a linear scale. For α-particles or low energy 
neutrons (said to be densly ionizing), the dose-response curve is a straight line from the origin (i.e., 
survival is an exponential function of dose). The survival curve can be described by just one parameter, 
the slope. For X- or γ-rays (said to be sparsely ionizing), the dose-response curve has an initial slope, 
followed by a shoulder; at higher dose, the curve tends to become straight again. A: The linear 
quadratic model. The experimental data are fitted to a linear quadratic function. There are two 
components of cell killing: One is proportional to dose (αD); the other is proportional to the square of 
the dose (βD2). The dose at which the linear and quadratic components are equal is the ratio α/β. The 
linear quadratic curve bends continuously but is a good fit to experimental data for the first few 
decades of survival. B: The multitarget model. The curve is described by the initial slope (D1), the final 
slope (D0), and a parameter that represents the width of the shoulder, either n or Dq (Hall, 2006). 
that do become straight exponential at higher dose” (Hall, 1993). Thus, LQ model 
overestimates the effect of radiation on clonogenicity in the high dose commonly used in 
SBRT and inappropriate to apply at the high doses per fraction encountered in radiosurgery 
because it (1) does not accurately explain the observed (in vivo) data; (2) was derived largely 
from, in vitro, rather than in vivo, observations and, thus, does not consider the impact of 
ionizing radiation on the supporting tissues; (3) does not consider the impact of 
subpopulation of radioresistant clonogens (ie, the “cancer stem cell” response); and (4) 
creates a “false belief” that this simplified model represent an absolute truth (Kirkpatrick, 
2008). Substantial modifications are needed to apply the LQ model to the SBRT regimen; at 
which point the model loses its simplicity and natural appeal (Guerrero & Li, 2004). The 
multitarget model (Fig. 2B) provides an alternative description of the clonogenic survival as 
a function of radiation dose and is still valuable because it fits the empirical data well, 
especially in the high dose range. In a study of University of Texas, Park et al proposed a 
new model, universal survival curve (USC), to reconcile the strengths of these LQ model 
and multitarget model into single, unifying model and stressed that the proposed survival 
curve model (Fig. 3) (Park, 2008).  
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Figure 3. Universal survival curve (USC) and transition between dose range at which linear quadratic 
(LQ) model is valid and dose range at which multitarget model is valid. Below transition dose DT, USC 
curve is identical with LQ model curve and above DT, USC curve is identical with terminal linear 
portion of multitarget model curve. 
The USC model can be used to derive isoeffective relations (equivalent dose function) of any 
arbitrarily fractionated RT. For SBRT, a novel concept of the single fraction equivalent dose 
(SFED) can serve as an alternative and more intuitive way to compare different dose 
fractionation schemes. SFED was defiend as the dose delivered in a single fraction that 
would have the same biologic effects as the dose fractionation scheme in question. For total 
dose D given in n fractions, each fraction with the dose, d, SFED is determined by the 
intersection line crossing the effective survival curve at D=d*n (Fig. 4) (Park, 2008).  
 
Figure 4. Graphic representation of stereotactic body radiotherapy (SBRT) and conventionally 
fractionated radiotherapy (CFRT) effective survival curves compared with single fraction equivalent 
dose (SFED) and biological effective dose (BED). Note, DCFRTand DSBRT are always situated between 
biologically equivalent dose parameters of SFED and BED. 
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The definition of BED and SFED using the USC curve remain applicable for any 
fractionation regimen. The ln S in fractionated conventional fractionated radiation therapy 






0 q 0 T
ln S  n * * d * d  if d D (A)
n * 1 / D * d –  D / D  if d D (B)
    
    (2) 
Thus, Equations. 2A and 2B are arranged to reflect the common clinical practice in designing 
dose fraction scheme in which dCFRT and nCFRT is varied for CFRT, and nSBRT is fixed and dSBRT 
is varied for SBRT. By letting dCFRT=2 Gy, the equation for DCFRT can be used to calculated the 
standard effective dose (SED), total dose in 2 Gy fractions with equivalent effect (see 
Equation 3A and 3B). 
  
 
    SBRT 0 CFRT CFRT SBRT qCFRT 0 SBRT SBRT q CFRT
D * D * D * 1 d / / n * D (A)
D 1 / * D D n * D / 1 d / / (B)
  
  
    
       
 (3) 
From the report of 12 non small cell lung cancer cell lines from National Cancer Institute, the 
value for α, D0 or Dq was obtained by determining the arithmetic mean values of each 
parameter. The range of Dq was wide, between 1.5 Gy and 2.5 Gy. The mean value for α, D0, 
and Dq was 0.33 Gy-1, 1.25 Gy and 1.8 Gy, respectively (Carmichael, 1989; Morstyn, 1984). 
The transition dose, DT was calculated to be 6.2 Gy, reassuring results, because the dose per 
fraction used in CFRT is < 6.2 Gy and SBRT regimens commonly use a dose per fraction > 6.2 
Gy. This USC is a new model that may offer a superior description of the mammalian cell 
survival curve in the ablative dose range beyond the shoulder, on the same time, preserving 
all the strengths of the LQ model in the low dose range (around the shoulder). However, the 
true survival of in vivo tumors depends on multiple factors that cannot possibly be 
contained in simplified mathematical formulas. The only way to truly know the tumor 
control rates or the tolerance of different fractionation schemes is through performing 
prospectively designed trial. 
3.3. Variable imaging technique to guarantee high accuracy radiotherapy 
In delivering SBRT, many commercially available units can be utilized. Sophisticated image 
guidance is a common feature to these treatment units. Units equipped with online image-
guided radiation therapy (IGRT) capability minimize the uncertainty associated with tumor 
localization. In-house developed systems such as RT-RT and CT-on-rails were employed 
prior to the widespread availability of in-treatment-room imaging. Recent developments 
have spread the availability of in-treatment-room imaging to many facilities. 
3.3.1. Cone beam CT Linear accelerator IGRT 
The first commercially available cone beam CT (CBCT) IGRT system was the Elekta 
Synergy™ (Elekta, Crawley, UK), the other medical linear accelerator (linac) manufacturers 
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have also now embraced the IGRT concept and have either produced their own version of 
an IGRT linac, Varian Trilogy™ (Varian Medical Systems, Palo Alto, Calif., USA), or are in 
the process of such developments, Siemens ARTÍSTE™ (Siemens Medical Solutions USA, 
Inc., Malvern, Pa.,USA). The Synergy and Trilogy consists of a retractable kV X-ray source, 
an amorphous silicon flat panel imager mounted on the linear accelerator perpendicular to 
the radiation beam direction, and a software module (referred to as the XVI system). The 
system provides planar, motion, and volumetric images.  
For CBCT image acquisitions, the gantry is rotated around the patient for a preset angle 
(between 180° and 360° to allow sufficient data acquisition) and images are acquired via an 
amorphous silicon panel.  Volumetric image reconstruction is performed simultaneously 
with the acquisition to expedite the process.  The reconstructed three-dimensional geometry 
is subsequently registered with the reference geometry planning image, either manually or 
automatically (using either soft tissue or bone mode). For some disease sites, such as 
prostate cancer, the soft tissue mode is conceptually ideally suited, since the prostate often 
moves relative to the bones. However, at present, it is difficult to visualize the prostate in all 
cases, and thus implanted radiopaque seeds are used to make the registration process more 
efficient.  Based on the registration, the difference between the data sets is calculated and 
displayed as translation along and rotation about the three axes. Subsequent treatment table 
adjustments are made and the patient treated. One can clearly appreciate that CBCT-based 
IGRT shows great potential for objective, precise positioning of patients for treatment, 
matching the treatment setup image model to that of the planning image model. It remains 
to be determined exactly which imaging features on the integrated CBCT linacs (i.e.,  kVp 
CBCT,  planar,  motion,  and MV electronic portal imaging device) are best suited for a 
particular disease site. 
3.3.2. Helical tomotherapy IGRT 
Helical tomotherapy was first proposed by Mackie et al. in 1993 and is now commercially 
available as the TomoTherapy HI -ART system (TomoTherapy, Inc., Madison, Wisc., USA). 
A short in-line 6-MV linac (Siemens Oncology Systems, Concord, Calif., USA) rotates on a 
ring gantry at a source-axis distance of 85 cm. The IMRT treatment is delivered while the 
patient support couch is translated in the y-direction (toward the gantry) through the gantry 
bore, in the same way as a helical CT study is conducted. In the patíent’s reference frame, 
the treatment beam is angled inwards along a helix with the midpoint of fan beam passing 
through the center of the bore. Similar to helical CT, the treatment beam pitch is defined as 
the distance traveled by the couch per gantry rotation, divided by the field width in the y-
direction. The width of the beam in the y-direction is defined by a pair of jaws that is fixed, 
for any particular patient treatment, to one of three selectable values (1, 2.5 or 5 cm). 
Laterally, the treatment beam is modulated by a 64 leaf binary multileaf collimator, whose 
leaves transition rapidly between open and closed states providing a maximum possible 
open lateral field length of 40 cm at the bore center. Highly modulated treatments can 
achieve great conformality, though they inevitably take longer to deliver. A helical MV CT 
image is acquired prior to treatment each day using the on-board xenon CT detector system 
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and the 6-MV linac (detuned to 3.6 MV). Registration software is provided to compare the 
daily patient setup image with the stored prescription CT planning image. After image 
registration, table adjustments are then automatically made and the patient is then treated. 
3.3.3. Megavoltage Cone Beam CT Linear Accelerator IGRT 
The only MV Cone Beam CT (CBCT) system currently available is the most recent addition 
to the family of in-room 3D systems designed for IGRT. The MV CBCT imaging system 
consists of a 6-MV x-ray beam produced by a conventional linear accelerator (Oncor, 
Siemens AG, Erlangen, Germany) equipped with an amorphous-silicon EPID (AG9-ES, 
PerkinElmer Optoelectronics, Waltham, MA., USA) flat panel detector. The system is 
controlled by a computer workstation (Syngo Coherence RTT, Siemens AG, Erlangen, 
Germany) that is responsible for all tasks related to portal or MV CBCT imaging, including 
calibration of the system, quality assurance, image acquisition, and image registration (2D or 
3D) for patient alignment. The use of MV photons for imaging is a departure from 
conventional preferences of using kilovoltage (kV) photons, which have resulted in superior 
image quality for diagnostic purposes. The MV CBCT system is capable of measuring setup 
errors of fiducials in an anthropomorphic head phantom with submillimeter accuracy and 
reproducibility. The gantry rotates in a continuous 200° arc (270° to 110°) while acquiring 
one low-dose portal image per degree. The 200 projection images acquired are then used for 
MV CBCT reconstruction, which is completed approximately 2 minutes after the starts with 
an automatic registration, based on a maximization of mutual information algorithm, which 
utilizes all information in both 3D images to maximize the alignment of similar structures.  
Routine quality assurance on the system has also demonstrated that the calibrated MV 
CBCT imaging isocenter remained within 1 mm to the machine treatment isocenter over a 
period of 1 year. As for the field-of-view, anatomical information situated in a 27  X 27  X 27 
cm3 volume centered at isocenter is reconstructed in the MV CBCT system with a half-beam 
acquisition mode should increase the reconstruction size in the axial plane by up to 40 cm. 
3.3.4. Vero IGRT 
Vero SBRT is specifically designed for IGRT and a new type of 6 MV linac with attached 
MLC is mounted on an O-ring gantry. The MLC consists of sixty 5-mm-leaves and produces 
a maximum field size of 150 x 150 mm2. The gantry rotates 360 degree and the horizontal 
axis, similar to a C-arm linac platform, but additionally allows rotation about the vertical 
axis. The system incorporates the MHI-TM2000 linear accelerator and sophisticated software 
to deliver radiation therapy. The system is equipped with a dual orthogonal kV imaging 
systems attached to the O-ring at 45 from the MV beam. This imaging system allows 
simultaneous acquisition of orthogonal X-rays images and fluoroscopy. Also kV CBCT 
imaging is available. Vero SBRT dynamically contours the treatment beam exactly to the 
tumor from every angle as the machine moves around the patient. Furthermore, Vero’s 
technology allows clinicians to dynamically treat with a moving beam in order to spare 
surrounding healthy tissue and organs while maximizing such as x-ray, CT and 
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fluoroscopy, so that clinicians can modify their plans during treatment as needed. The 
targeted beam adapts to breathing and other body movements to maintain safe, complete 
and accurate dose delivery.   
3.3.5. Electromagnetic tracking 
One of the earliest applications of electromagnetic tracking in RT was for the 
nonradiographic localication of interstitial abdominal implants for intraoperative high-dose-
rate (HDR). In this application a then-commercially available 3SPACE-FASTRAK system 
(Polhemus Inc, Colchester, VT., USA) was configured to fit in the lumen of a catheter. The 
system was then used to measure the spatial path of all catheters by inserting the wired 
sensor sequentially into each catheter. This information was then used by the planning 
system to accurately determine and calculate dwell positions and times. The stated accuracy 
of the system was a root mean square (RMS) of 0.8 mm, but measurements in the operating 
environment found the RMS accuracy to be 0.38 mm in the absence of metallic surgical 
retractors and 0.70 mm in the presence of three retractors, with maximum absolute errors of 
2.1 mm or less. 
In 2000, the Paul Scherrer Institute reported on an electromagnetic tracking system they had 
developed for real-time (50 Hz) target volume tracking during proton therapy with 
continuous spot scanning delivery. This system consisted of an external magnetic field 
generator, a wired implantable sensor, and the associated signal processing electronics. 
When compared with an optical tracking device with 30 μm accuracy, the RMS spatial 
accuracy was reported to be 1 mm to 2 mm, whereas the RMS angular accuracy of 
determining the orientation of the dipole was 0.5 to 1 degree. The system’s ability to track 
and gate was tested in a moving phantom and qualitatively shown to very nearly restore the 
dose distribution to the planned static distribution when a 3-mm gating window was 
implemented. The technology for this system was developed by a spin-off company from 
the Paul Scherrer Institute called Mednetix AG, which was acquired by Northern Digital Inc 
(Waterloo, ON, Canada). Further development efforts have focused on a wired 
electromagnetic tracking system for guidance of medical instruments, which is 
commercially available in the Aurora system.  
3.3.6. Cyberknife IGRT 
The use of a small X-band linear accelerator mounted on an industrial robot was first 
developed for radiosurgery. The robot provides the capability of aiming beamlets with any 
orientation relative to the target volume. The system uses two ceiling-mounted diagnostic X-
ray sources, and amorphous silicon image detectors mounted flush to the floor. The 
treatment is specified by the trajectory of the robot and by the number of monitor units 
delivered at each robotic orientation. During the patient's treatment, the Cyberknife System 
correlates live radiographic images with preoperative CT or MRI scans in real time to 
determine patient and tumor position repeatedly over the course of treatment. More details 
are provided by users of this system in subsequent articles in this volume. 
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3.4. Compensation of respiratory motion of the tumor and internal organ 
SBRT requires precise delineation of patient anatomy, targets for planning, and clear 
visualization for localization during treatment delivery. Three-dimensional data sets 
assembled from CT or 4DCT for visualizations and dose calculation and/or MRI and 
positron emission tomography (PET) images assist in target and visualization for SBRT.  
3.4.1. Four-Dimensional CT scanning 
Respiratory correlated 4DCT was developed over the past several years to address the 
issues of respiratory motion in radiotherapy targeting (Rietzel, 2005). Respiration-correlated 
CT uses a surrogate signal, such as the abdominal surface, respiratory air flow, or internal 
anatomy to provide a signal that permits resorting of the reconstructed image data, resulting 
in multiple coherent spatiotemporal data sets at different respiratory phases. The scan time 
for 4DCT with multi-slice scanners is on the order of a few minutes, and post-processing 
takes an additional 30 min if manual phase selection is required. The output of this process 
is typically 10 CT volumes, each with a temporal resolution of approx. 1/10 of the 
respiratory period. 4DCT uses multi-slice CT scanners combined with a respiratory 
surrogate to develop a series of 3DCT scans each representing the patient in a different 
respiratory phase. The entire 4DCT dataset can be used to determine an envelope of tumor 
motion which can be expanded to include areas of subclinical disease resulting in an 
internal target volume (ITV) (ICRU 1999) which can be used as the treatment target. 
Alternatively, select phases from the 4DCT can be used to determine an ITV that only covers 
a select range of respiratory phases (i.e. 40%-60% corresponding to a ± 10% window around 
end exhalation) that would be the target for gated treatments. The most common form of 
motion management used in RTOG studies to date and also at many experienced centers 
using SBRT across the world has been chest wall breathing with abdominal compression. 
Chest wall breathing exerts forces on the intrathoracic tissues in multiple opposing 
directions in contrast to the mostly craniocaudal force vectors associated with 
diaphragmatic breathing. As a result, the amplitude of tumor motion with chest wall 
breathing can be significantly decreased. With this technique, the patient is first coached to 
expand the lungs using their upper chest wall rather than by moving their diaphragm 
toward their abdomen. 
The 4DCT implementation relies on sensing the respiratory phase by using the Varian RPM 
system or Anzai system. 4DCT provides an imaging tool to quantify and characterize tumor 
and normal tissue shape and motion as a function of time. This provides the radiation 
oncologist and treatment planner with information essential in the design of an aperture 
that more adequately covers the internal target volume (assuming respiration during 
treatment is reproducible to that during CT simulation). 4DCT data can also be used as 
input in making treatment decisions on when to intervene with gating or other motion 
management strategies. In addition, the 4DCT data can be used as direct input into four-
dimensional treatment planning, and to generate time-varying dose-volume histograms or 
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isodose distributions. An effective method of conveying the utility of 4DCT is through 
computer animation. Dr. Choi et al. [pers. commun., 2005] have found that approximately 
one half of patients with early-stage disease have motion of less than 10 mm during quiet 
breathing (in approx. 100 cases). Seppen woolde et al. reported on the motion of 21 lesions 
in 20 patients and found a mean motion of 5.5 mm in the craniocaudal direction (data 
ranged from 0 to 2.5 cm). Average periodicity was observed to be 3.5 s, and ranged from 2.8 









Figure 5. Overview of respiratory phase “bin” generation from four-dimensional computed 
tomography data. 
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3.4.2. Image registration & Motion management 
SBRT treatments do not use invasive external frames. A body frame system has been 
developed that incorporates several features to ensure reproducible setup, including a 
vacuum bag that is fit to the patient at the time of simulation, a scale that facilitates 
reproducible positioning of the patient in the frame, an abdominal compression paddle to 
restrict abdominal motion, and external fiducial markers to improve setup accuracy (Lohr, 
1999; Hadinger, 2002). This system is particularly useful when the patient is to be imaged in 
one room and the entire patient/body frame system is moved to the treatment room. 
Without a body frame, either implanted fiducial markers or in-room volumetric imaging is 
required for accurate internal soft tissue-based setup.  
One technique for minimizing the effects of respiratory motion is to activate the radiation 
beam only when the tumor is at a predetermined location in the respiratory cycle. This is 
referred to as respiratory gating (Shirato, 2000; Starkschall, 2004; Nelson, 2005; Underberg, 
2005). The use of gating requires some measure of the tumor location within the respiratory 
cycle, which can be done directly but is more often done through some respiratory surrogate 
such as abdominal height or diameter. Spirometry has also been used to gate based on tidal 
volume (Zhang, 2003). 
Alternative motion management techniques include dynamic gating and breath-hold 
techniques. During dynamic gating the patient is allowed to breath normally with or 
without audio or visual coaching and the radiation beam is activated only when the patient 
reaches the planned points in their respiratory cycle. Breath-hold gating requires the patient 
to hold their breath at a given abdominal height or tidal volume generally with the aid of 
visual feedback and the radiation beam is activated only when the patient is holding their 
breath in this target position. The breath-hold can either be voluntary or assisted with an 
occlusion valve. Breath-hold has several benefits over dynamic gating including the ability 
to do volumetric imaging over a series of breath holds, longer irradiation times to allow 
radiotherapy beams to stabilize, and the ability to expand the lungs and give more fall-off 
distance between the target and nearby critical structures. 
Gating is performed with real time or near time verification of the target position in the gate 
with in-treatment-room imaging. An early example of in-treatment-room imaging was 
developed by Shirato et al. (Shirato, 1999) who developed a real-time tumor tracking 
method in which four sets of x-ray tubes and fluoroscopic imagers are used to measure the 
position of four implanted radiopaque markers relative to the isocenter. The linear 
accelerator was configured so that it irradiated the tumor only when the markers were 
within certain coordinates. This system is effective for the treatment of lung tumors but 
requires the invasive implantation of fiducial markers. In addition this system has not 
become commercially available. A similar method is used by two commercially available 
stereotactic systems, Novalis®/Exactrac® (BrainLAB, Feldkirchen, Germany) (Yin, 2002) and 
Cyberknife® (Accuray, Sunnyvale, CA) (Adler, 1997). These systems both have room 
mounted orthogonal x-ray systems that can observe the patient’s anatomy in the treatment 
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position. Implanted fiducial markers are required for all lung tumors on the Novalis® 
system but the Cyberknife® can use either fiducial markers or direct imaging depending on 
the tumor location. The Novalis® system does not employ real-time tumor tracking but 
rather relies on a relationship between external surrogates and the tumor position 
developed immediately prior to treatment. Cyberknife® can either confirm the position of 
the target at regular intervals during treatment or utilize a respiratory tracking system that 
continuously synchronizes beam delivery to the motion of the target.  
Non-radiographic localization was investigated by Balter et al. (Balter, 2005) who studied 
the use of the Calypso™ 4D system for patient positioning based on real-time localization of 
implanted electromagnetic transponders (beacons). This study demonstrated the accuracy of 
the system before clinical trials were conducted. The system consists of 5 major components: 
wireless transponders, a console, a detector array, a tracking station and infrared cameras. 
The array emits electromagnetic radiation that excites the implanted transponders. Due to 
the resonance response the array can locate the 3D coordinates of the wireless transponders. 
The infrared cameras allow the registration of the position of the array relative to the 
isocenter of the linear accelerator. This system offers the potential for real-time tracking and 
is commercially available for prostate but not yet for other body sites including the lungs.  
3.5. Quality Assurance of SBRT  
An important goal of a quality assurance (QA) program is to instill confidence that patients 
are receiving their prescribed treatments accurately. The goal should not be simply getting 
through some mandatory tests as quickly and painlessly as possible. Unfortunately, many 
catastrophic events are produced by failures happening at a moment that cannot be 
predicted or caught by routine quality control (QC) procedures. As there are built-in 
interlocks in treatment devices, most failures occur in human processes rather than in 
equipment. Finding the proper balance between effort spent on specific QC procedures and 
effort spent on an overall quality management program is major challenge at most 
institutions.  
The QA program for an SBRT process based on IGRT system must evaluate the entire 
treatment process, including patient immobilization, setup, simulation imaging, treatment 
planning (including the production of reference images to guide corrections), verification 
imaging, image registration, patient position correction, and treatment. Tests that assess the 
entire process from beginning to end inspire confidence that the overall process is accurate 
and robust. In such as study, planning images of a phantom are acquired and transferred to 
the treatment planning system. A treatment plan is designed and reference images are 
produced. The phantom is then taken to the treatment unit and positioned for treatment. A 
verification images is acquired and registered to the reference image. Any necessary 
corrections to the position are made. Treatment is then delivered and measured by using an 
ion chamber and/or film. The dosimeter readings are compared with the expected values 
from the treatment plan. The frequency of such tests should be based upon an analysis of 
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system stability during the initial operation of the SBRT system. Also, the image-guidance 
procedures should be reviewed on a regular basis to ensure that the procedures are 
consistent with the initial design and to initiate appropriate changes if necessary. The review 
results and any new changes must be communicated among staff. The review of the 
guidance elements of a patient’s treatment can be integrated into the institutional chart 
rounds and quality control programs to verify that the image guidance procedure is 
operating correctly. 
Conventional linear accelerator-based IGRT consists of imaging in the treatment room 
during a course of radiotherapy. Planar (two-dimensional [2D]) and volumetric (three-
dimensional [3D]) imaging are used for repositioning the patient immediately prior to 
treatment.  The common elements of a QA program include: (1) safety and functionality, (2) 
geometric accuracy (agreement of MV and kV beam isocenters), (3) image quality, (4) 
registration and correction accuracy, and (5) dose to patient and doseimetric stability.  
Helical Tomotherapy requires synchrony of gantry rotation, couch translation, linear 
accelerator pulsing, and opening and closing of the binary MLC leaves used to modulate the 
radiation beam. The accuracy of this highly dynamic treatment process depends on the 
correct performance of the radiation source, MLC, gantry, and couch table. The dose 
delivered to the patient depends on the static beam dosimetry, system geometry, system 
dynamics, and system synchrony. Systematic QA of the system dynamics and synchrony 
has been suggested, which includes jaw width constancy, actual fraction of time leaves are 
open, couch drive distance, speed and uniformity, linear accelerator pulsing and gantry 
synchrony, leaf opening and gantry synchrony, and couch drive and gantry synchrony. 
Quality assurance programs for IGRT are not easy to implement. Rapid development of new 
IGRT techniques and devices is quickly making traditional QA guidelines outdated. Because 
of the diversity of IGRT, it is extremely difficult to develop industry-wide specific QA 
guidelines, forcing a conversion to process-centered quality management guidelines, which 
each institution can tailor to its individual needs. An optimal QA program is always a 
balance between available resources, manpower, and time to perform the work. 
Patient-specific QA procedures for SRS/SBRT should be developed as an integrated part of a 
comprehensive ongoing QA program in the clinic. Therefore, before implementing an SBRT 
program, the clinic first needs to determine which system(s) will be used and develop QA 
procedures to match. SBRT-enabled systems often have specialized equipment such as 
immobilization systems, localization systems, and on-board imaging systems which are not 
always found in the clinic. In other cases, the entire system is specialized for SBRT (e.g. the 
Accuray Cyberknife). For example, Table 1 summarizes the stereotactic localization and 
image guidance strategies used by commercially-available systems. These specialized 
components require detailed and specialized QA procedures, over and beyond the general 
guidelines for external beam radiotherapy as specified in the AAPM Reports of TG 40, 142, 
and 45.  
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Author Site Immobilization/repositioning Reported accuracy 
Lax, 1994 Abdomen Wood frame/stereotactic coordinates 
on box to skin marks 
3.7 mm Lat. 5.7 mm 
Long 
Hamilion, 1995 Spine Screw fixation of spinous processes 
to box 
2 mm 
Murphy, 1997 Spine Frameless/implanted fiducial 
markers with real-time imaging and 
tracking 
1.6 mm radial 
Lohr, 1999 Spine Body cast with stereotactic 
coordinate 
≤ 3.6 mm mean vector 
Yenice, 2003 Spine Custom stereotactic frame and in-
room CT guidance 
1.5 mm system 
accuracy, 2-3 mm 
positioning accuracy 
Chang, 2004 Spine MITM BodyFix with stereotactic 
frame/linac/CT on rails with 6D 
robotic couch 
1 mm system accuracy 
Tokuuye, 1997 Liver Prone position jaw and arm straps 5 mm 
Nakagawa, 
2000 
Thoracic MVCT on linac Not reported 
Wulf, 2000 Lung, liver ElektaTM body frame 3.3 mm Lat. 4.4 mm 
long 
Fuss, 2004 Lung, liver MITM Body Fix Bony anatomy 
translation 0.4, 0.1, 1.6 
mm (mean X, Y, Z); 
tumor translation before 
image guidance 2.9, 2.5, 
3.2 mm (mean X, Y, Z) 
Herfarth 2001 Liver Leiginger body frame 1.8 – 4.4 mm 
Nagata, 2002 Lung ElektaTM body frame 2 mm 
Fukumoto, 
2002 
Lung ElektaTM body frame Not reported 
Hara, 2002 Lung Custom bed transferred to treatment 
unit after confirmatory scan 
2 mm 
Hof, 2003 Lung Leibinger body frame 1.8 – 4 mm 
Timmerman, 
2003 
Lung ElektaTM body frame Approx. 5 mm 
Wang, 2006 Lung Medical Intelligence body frame 
stereotactic coordinates/CT on rails 
0.3±1.8 mm AP. -1.8±3.2 
mm Lat. 1.5±3.7 mm SI 
Table 1. Achievable accuracies reported in the literature categorized by body site and 
immobilization/repositioning device.(AAPM TG101) 
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Source Purpose Proposed test Reported 
achievable
Proposed frequency 





Stereo x ray/DRR 
fusion 
























Hidden target (using 
stereo x ray/DRR 
fusion)










Hidden target (using 
implanted fiducials)











assessment of hidden 
target (using 
implanted fiducials)














0.50 ± 0.5 mm Baseline at 
commissioning and 
monthly thereafter 








modified to make 
use of the in-room 
imaging system 






Palta et al., 
2008 
MLC accuracy Light field, 
radiographic film or 
EPID 










Hidden target in 
anthropomorphic 
phantom
1.0 ± 0.42 mm Initial 
commissioning and 
annually thereafter 
Jiang et al., 
2008 
Respiratory motion 






et al., 2008 
CBCT geometric 
accuracy 
Portal image vs 
CBCT image 
isocenter coincidence
2 mm daily 
Table 2. Summary of published QA recommendations for SBRT and SBRT-related techniques. .(AAPM 
TG101) 
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4. Clinical aspect 
4.1. Proper selection of patients  
The most important goal of SBRT in oligometastases is to achieve local control, however, 
whether obtaining local control of the metastasis would translate into clinical or survival 
benefit of the patients is dependent on multiple factors, including age, performance status, 
medical comorbidities and histology of malignancies. Therefore, the patients’ whole condition 
should be fully considered. In general, patients with younger age, high performance status, 
controlled primary sites, limited number of metastases from three to five or fewer, 
metachronous occurrence of primary disease and metastatic disease, histologies, such as 
colorectal carcinoma, breast cancer and radioresistant cancer including renal cell ca, melanoma 
and sarcoma, are most likely to benefit from SBRT of their oligometastases (Carey-Sampson et 
al, 2006). In addition, SBRT delivers the individual ablative radiation doses to a planning target 
volume with a steep dose gradient outside the lesion treated and it is crucial that the lesions to 
be treated must be easily delineated on diagnostic imaging. 
4.2. Lung metastases 











8 92 Med.S 11.3mo 




9 98  
Nakagawa et 
al, 2000 
retrospective 14/21 16-24Gy/1fx 10 95 2YOS 35% 
Wulf et al, 2001 retrospective 41/51 30-37.5 Gy/3fx ; 
26 Gy/1fx 
14 80% 2YOS 33% 
Hara et al, 2002 retrospective 14/18 20-30Gy/1fx 12 78  
Lee et al, 2003 retrospective 19/25 30-40 Gy/3-
4fx 
18 88 Med.LPFS 
18mo 
Hof et al, 2007 retrospective 61/71 12-30 Gy/1fx 14 88.6 (1YR) 3YOS 47.8% 
Okunieff et al, 
2006 
retrospective 42/125 50 Gy/10fx 18.7 94 Med.S 23.4mo 
Norihisa et al, 
2008 
retrospective 34/43 48-60 Gy/4-
5fx
27 90 2YOS 84.3% 
Kim et al, 2009 retrospective 31/134 50 Gy/10fx 16 87.1 Med.S 16mo 
Ernst-Stecken 
et al, 2006 







prospective 38/63 48-60 Gy/3fx 15.4 96 Med.S 19mo 
Table 3. Results of SBRT in lung metastases 
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There are numerous retrospective studies on the use of SBRT for the treatment of lung 
oligometastases from North America, Europe and East Asia (Table 3). Early results from 
Blomgren’s and Uematsu’s studies showed excellent local control rates of 92% and 98%, 
respectively although the follow up periods were short (Blomgren et al, 1995; Uematsu et al, 
1995). Subsequently, Nakagawa treated 14 patients with 21 tumors with SBRT to a single dose 
of 16 to 24 Gy. The local control rate and 2 year overall survival rate were 95% and 35%, 
respectively (Nakagawa et al, 2000). In a report of Wulf et al, the 41 patients with 51 metastatic 
lung tumors were treated with SBRT of 30 to 37.5 Gy in 3 fractions or 26 Gy of a single dose. 
The crude local control rate was 80% at a median follow up 14 months and 2 years overall 
survival rate was 33% (Wulf et al, 2001). And Hof et al also treated 61 patients with 71 lung 
metastases with SBRT to a single dose of 12 Gy to 30 Gy. The actuarial local progression free 
rate was 79% at 1 year and overall survival rate was 47.8% on 3 years (Hof et al, 2007). In a 
report of Okunieff et al, they treated 50 patients with five or fewer lung metastases with SBRT. 
At a median follow up of 18.7 months, 94% local control rate and 50% of 2 years overall 
survival rate were yielded (Okunieff et al, 2006). Kim et al also treated the patients with 
multiple lung metastases with SBRT to a dose of 50 Gy in 10 fractions during 2 weeks. The 
local control rate was 87.1% and median survival time was 16.0 months (Kim et al, 2009). Two 
prospective studies’ outcomes were also shown in table 3. In a report from Germany, Ernst-
Stecken et al reported the results of dose escalating phase I/II trial of SBRT for lung tumors, 
Overall, 21 patients (three with primary lung tumors) with 39 tumors were treated with SBRT 
starting at dose level of 35 Gy (7 Gy x 5) and the dose was then escalated to 40 Gy (8 Gy x 5). In 
total, 21 and 18 tumors were treated to 35 Gy and 40 Gy, respectively. Rates of complete 
response, partial response, stable disease and progressive disease were 51%, 33%, 3% and 13%, 
respectively (Ernst-Stecken et al, 2006). In 2009, in a multi-institutional phase I/II trial of SBRT 
for patients with 1 to 3 lung metastatic tumors less than 7 cm diameter, the total radiation dose 
was safely escalated from 48 Gy to 60 Gy in 3 fractions. The 2 year actuarial local control rate 
was 96% and median survival time was 19 months (Rusthoven et al, 2009). 
4.3. Liver metastases 
 type No of pts
/targets
Dose(Gy/fx) FU (mo) LC(%) Survival 
Blomgren et al, 
1998 
retrospective 17/21 20-40 Gy/1-2fx 9.6 95  
Katz et al, 2007 retrospective 69/174 30-55Gy/2-6fx 14.5 76-57 Med.S 
14.5mo 
Wulf et al, 2001 retrospective 23/23 28-30Gy/2-4fx 9 76-61  
Herfarth et al, 2001 prospective 33/56 14-26Gy/1fx 18 67 1YSR 72% 
Kanavagh et al, 
2006 
prospective 21/28 36-60Gy/3fx 18 93  
Mendez-Romero 
et al, 2006 
prospective 17/34 37.5Gy/3fx 12.9 100-86  
Table 4. Results of SBRT in liver metastases 
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Blomgren’s early data on SBRT for liver metastases showed promising results of 95% local 
control rate on 9.6 months follow up (Blomgren et al, 1998). In the study of University of 
Rochester, which represents the largest study in SBRT for liver metastases, Katz et al treated 
69 patients with 174 liver metastases with SBRT to a median dose of 48 Gy(range, 30-55Gy) 
in 2 to 6 fractions. The mean number of lesions was 2.5 (range, 1-6). The most common 
primary sites were colorectal (n=20) and breast (n=16). The median follow up was 14.5 
months. The local control rates were 76% and 57% at 10 and 20 months, respectively. The 
median overall survival time was 14.5 months (Katz et al, 2007). Wulf et al reported their 
experience on 23 patients treated with SBRT for liver metastases. The prescribed dose was 30 
Gy in three fractions. The actuarial local control rates on one and two year after treatment 
were 76 and 61%, respectively (Wulf et al, 2001). Herfarth et al performed a dose escalation 
study utilizing single dose SBRT from 14 Gy to 26 Gy. Fifty six liver metastases of 33 
patients were treated and their local control rate was 67% on 18 months after treatment. 
Local failures were observed mainly in patients treated to a lower dose. For patients treated 
to higher dose (>20 Gy), the actuarial local control rate was 81% (Herfarth et al, 2001). In a 
study of Colorado University, Kavanagh et al reported 93% of actuarial local control rate on 
18 months and indicated that a very high rate of durable in-filed tumor control can be safely 
achieved with SBRT to one to three liver lesions to a prescription dose of 60 Gy in 3 fractions 
(Kanavagh et al, 2006). Mendez-Romero et al reported the results of 17 patients with 34 
metastatic liver tumors treated in phase I/II study of SBRT. The prescribed dose was 37.5 Gy 
in 3 fractions. The actuarial one and two year local control rates were 100% and 86%, 
respectively and the actuarial overall survival rate at one and two years were 85% and 62%, 
respectively (Mendez-Romero et al, 2006).  
4.4. Spine metastases 
SBRT has emerged as a novel treatment modality in the multidisciplinary management of 
spinal metastasis. Compared with conventional radiotherapy, SBRT can deliver a much 
higher biologic equivalent dose to the spinal tumor while respecting the dose constraints of 
the spinal cord or cauda equine, which are usually the dose limiting structures. The 
inclusion criteria for spinal SBRT are solitary or oligometastatic disease or bone only disease 
in otherwise high performance status patients, maximum of two consecutive or non 
contiguous spinal segments involved by tumor, failure of prior XRT (upto one course and 45 
Gy maximum) or surgery, non myeloma tumor type, gross residual disease or deemed to 
high risk for recurrence postsurgery, patients refusal or medical comorbidities precluding 
surgery, gross tumor optimally more than 5 mm from the spinal cord, Karnofsky 
performance status > 40-50, MRI- or CT documented spinal tumor, histologic confirmation 
of neoplastic disease and Age > 18. These are yielded from reports by various authors for 
spine SBRT. And these criteria are based on relevant studies, which include those reporting 
both the dose/fractionation used and duration of follow up for patients treated for 
metastatic spinal tumors. However, the final treatment recommendation should involve 
ideally a multidisciplinary tumor board composed of surgeons, radiation oncologists, 
medical oncologists, and medical physicists. 
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Table 5. Clinical Results of SBRT in spinal metastasis 
In a report from Henry Ford Hospital, Ryu et al treated 61 spinal tumors in 49 patients with 
single dose of SBRT alone to a dose of 10 to 16 Gy. With follow up time ranging from 6 to 24 
months, the local control rate was 93% on imaging and clinical response including complete 
or partial pain control was achieved in 52 of 61 tumors (85%) (Ryu et al, 2004). In a report of 
SBRT as reirradiation, Milker-Zable treated 19 tumors from 18 patients with a dose range 
from 24 to 45 Gy in 2 Gy fractions. Their previous median dose was 39.6 Gy in 2 Gy 
fractions. With a median follow up time 12 months, the clinical response rate was 95%. They 
defined PTV as a gross tumor volume plus entire vertebral body through CT with MRI 
fusion and defined spinal cord as spinal cord from MRI plus safety margin of 2 to 3 mm. 
Dose constraints of spinal cord on SBRT as reirradiation was maximal dose to spinal cord 
less than 20 Gy in 10 fractions to a median percent of spinal cord (Milker-Zabel et al, 2003). 
In a postoperative SBRT series from Pittsburg Medical center, Gerszten et al reported the 
results of SBRT using Cyberkinife from 26 tumors in 26 patients. The prescribed dose was 16 
to 20 Gy at the 80% isodose line with a median follow up of 16 months, the local control rate 
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was 92%. Pain control was evaluated using a ten point verbal visual analog scale and was 
improved in 24 out of 26 patients (Gerszten et al, 2005). And in the largest report from same 
group, Gerszten et al treated a total of 393 patients with 500 spinal metastases with 
Cyberknife based single dose SBRT to doses ranging from 12.5  to 25 Gy. Seven patients also 
received external radiation therapy. With a median follow up of 21 months, the local control 
rate was 88%. Among the 336 evaluable patients, 290 (86%) achieved improvement in pain 
based on a ten point visual analog scale (Gerszten et al, 2007). Sahgal et al reported the 
treatment results of Cyberknife based SBRT for spinal metastases from University of California 
SanFrancisco in abstract form. They treated 60 spinal metaststases in 38 patients with a dose 
ranging from 8 to 30 Gy in one to five fractions (median 24 Gy in three fractions). With a 
median follow up of 8.5 months, the local control rate was 87% and the pain improvement was 
achieved in 31 out of 46 tumor sites (67%) (Sahgal et al, 2007). In a phase I/II trial from MD 
Anderson Cancer Center, Chang et al reported the results of 63 patients with 74 tumors treated 
with SBRT to a dose of 30 Gy in five fractions or 27 Gy in three fractions. Thirty five patients 
had prior external radiotherapy. With a median follow up of 21.3 months, the local control rate 
was 77% and the one year progression free rate was 84% (Chang et al, 2007). 
4.5. Multiple organ oligometastases 
Authors No of 
pts/tumors
Sum of GTV Dose/fx FU (mo) Outcome 
Milano et al, 
2008 
121 /293 0.3-422 ml














volume   
10cm or < 
500cm3
24-36 Gy/3 5.3-27 
(med. 
14.9) 
Response rate 59%; 
PFSR 21%; LC 57% 





10cm or < 
500cm3
24-48 Gy/3 Med. 20.9 1 year OS/PFS  
81.5%/33.3%; 2 year 
OS/PFS 56.7%/22.0% 
Table 6. Clinical results of 5 or fewer oligometastases 
There are fewer reports about SBRT in multisite oliogometastases (Table 6). Among them 
the largest trial was performed in Rochester University hospital. Milano et al reported that 
the 4 year overall survival, progression free survival, local control and distant control were 
28%, 20%, 60% and 25%, respectively after SBRT for multiple sites oligometastases from 121 
patients. And they showed that number of metastases (range, 1~5) was not correlated with 
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treatment outcomes. Salama et al firstly performed dose escalation study of SBRT in patients 
with oligometastases involving multiple organs (Milano et al, 2008). In phase I/II trial, they 
treated 56 tumors in 29 patients with a dose to 24 to 36 Gy in 3 fractions. With a median 
follow up 14.9 months, local control and progression free survival rate were, 57% and 21%, 
respectively (Salama et al, 2008). In a final report from same group, Salama et al could 
escalate the dose from 24 Gy to 48 Gy in 3 fractions. Fifty six tumors in 29 patients were 
treated and their 1 and 2 year overall survival rate was 81.5% and 56.7%, respectively. And 
they showed superior outcome in the patient with one to three metastases to the others with 
four or five metastases (2 year overall survival; 60.3% vs 21.9%) but there was not statistical 
significance (p=0.22) (Salama et al, 2011). 
4.6. Dose constraints to prevent normal tissue toxicity 
SBRT has been defined as hypofractionated (1-5 fractions) extracranial stereotactic radiation 
delivery, thus when selecting the fractional and total dose, several clinical considerations are 
important, including; (1) predicted risks of late normal tissue complications; (2) predicted 
tumor control; (3) financial costs and time expenditure for treatment planning and delivery. 
Among these, the long term effect of hypofractionated dose delivery to small volumes of 
normal tissues is not well understood, and certainly more clinical studies with longer follow 
up are needed to better define the variable associated with risks of late toxicity. Table 7 
shows the normal tissue dose volume constraints to prevent late radiation complication in 
NCCN guidleline version 2.2012. 
OAR 1 fraction 3 fractions 4 fractions 5 fractions 


























































Table 7. Normal tissue dose volume constraints for SBRT from NCCN guidelines 
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The recommendation from Table 7 is frequently referenced in SBRT for non small cell lung 
cancer (Ettinger et al, 2012) and so, there is no information about intra abdominal organ 
including small intestine, liver and kidney. Radiobiologically, normal tissues can be 
categorized into two groups of serially arranged tissues and parallel arranged tissues. In a 
review article from Rochester University in New York, Milano et al recommended the 
fractional dose limitations to small volume of normal tissue which were expected to be safe 
with respect to risk of radiation necrosis in serially arranged tissues and they also noted the 
dose constraints of parallel arranged normal tissues such as lung, liver and kidney for safe 
SBRT in same article (table 8 and 9) (Milano, 2008). 
 
Number of fractions 
Normal tissue 1 3 5 8 10 
Spinal cord 8-10 Gy 5-6 Gy 4-5 Gy 3-4 Gy 3 Gy 
Trachea & bronchi - - 7-9 Gy 6-7 Gy 4-5 Gy 
Brachial plexus - - 8-10 Gy 6-7 Gy 5-6 Gy 
esophagus - - 6-8 Gy 4-5 Gy 3-4 Gy 
Chest wall/ribs - 10-15 Gy 6-8 Gy 6-7 Gy 5-6 Gy 
Small bowel  10-12 Gy 10-12 Gy 6-8 Gy 5-6 Gy 4-5 Gy 
Lung 20 Gy 20 Gy 8-10 Gy 7-8 Gy 5-7 Gy 
Liver 25 Gy 20 Gy 8-10 Gy 7-8 Gy 5-6 Gy 
Table 8. Recommendation for safe hypofractionated SBRT fractional dose to small volume of serially 
arranged tissues. 
Lung  700-1000 ml of lung not involved with gross disease or planning target volume 
V20 of 25-30% 
Liver  700-1000 ml of liver not involved with gross disease or planning target volume 
Two thirds of normal liver < 30 Gy 
Kidney  Minimize dose receiving > 20 Gy 
Two thirds of one kidney < 15 Gy (with another functional kidney) 
Table 9. Recommendation for safe hypofractionated SBRT dose volume metrics for parallel arranged 
normal tissues 
Deriving standard acceptable maximally effective and minimally toxic dose fractionation 
schemes presents a challenge, even with available outcome data. In fact, this complexity 
arises from not only the different dose-fractionation schemes used, but also in differences in 
how the dose is prescribed. Further study and longer follow up are needed to ascertain the 
dose fractionation schedule that optimizes tumor control while minimizing toxicity and to 
better understand the optimal normal tissue dose volume constraints. 
4.7. Patterns of failure  
A subset of patients with oligometastases have been alive a prolonged disease free state, 
some > 7 years, most eventually succumbed to further metastatic progression. There are 
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several studies which have examined the pattern of recurrence after resection, 
radiofrequency ablation, or cryosurgery and SBRT of oligometastases. Table 10 shows the 
literature summary of the pattern of recurrence after treatment of limited liver metastases. 
 
First author Sugihara et 
al, 1993 
Aloia et al, 
2006 
Kosari et al, 
2002 
Ravikumar 
et al, 1991 
Milano et al, 
2010 
Primary cancer colorectal colorectal various colorectal various 





64/107 (60%) 71/150 (57%) 23/45 (51%) 17/24 (71%) 37/42 (88%) 










Recurrence in      
Liver only - 18% 52% 35% 22% 
Extrahepatic only - 62% 4% 6% 5% 
Liver+extrahepatic - 20% 43% 59% 73% 
Liver 53% 38% 96% 94% 95% 
Lung  31% 58% - - 32% 
CNS - 1% - - 8% 
Bone - 6% - - 19% 
other 28% 17% - - 32% 
 
Table 10. The pattern of recurrence after local treatment of limited liver metastases 
All authors reported that the first new recurrence or metastases occurred quite commonly in 
the same organ, although metastases to other organs are common as well. New metastases 
occurring shortly after completion of treatment including SBRT presumably represents the 
growth of initially occult metastatic disease versus rapid metastatic progression, whereas 
new metastases that occurs after a longer time interval represents more indolent growth of 
initially occult metastatic disease versus a more remote occurrence of distant spread. 
However, a few present studies can determine a mechanism to account for new metastases. 
Some variables are thought important in predicting where subsequent metastases are likely 
to occur. The initial organ involvement, use of chemotherapy, type of local therapy, primary 
cancer type, histology and grade are expected to be important which can impact the pattern 
of subsequent recurrence. In addition, genotypic and phenotypic changes which lead to 
metastatic potential must exist and should be explained in the future. 
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5. Conclusion and future aspect 
In its current form, stereotactic hypofractionated radiotherapy is still in its infancy as an 
experimental treatment for oligometastases. At this point, a recommendation cannot be 
made for a fractionation scheme, which suggests the need for prospective investigation. 
There are multiple ongoing clinical trials on the use of SBRT for oligometastases in various 
body sites and the results of those trials are eagerly awaited. Given the high propensity for 
distant progression, the combination of novel systemic therapy and SBRT is to be explored. 
Interested readers can visit the web site (www.clinicaltrials.gov) to a full list of clinical trials 
of SBRT for various metastatic sites. 
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